Preparation method and application of barley leaf biotransformation product

Preparation of biotransformants by fermenting barley leaf powder from mice intestinal microorganisms has solved the problem of poor treatment effect of existing anti-inflammatory drugs, significantly improving the intestinal health of mice, including inhibiting weight loss, diarrhea and colon shortening, and reducing Colon tissue damage improves intestinal barrier function.

CN116406789BActive Publication Date: 2024-11-22CHINA AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310396460.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-13
Publication Date
2024-11-22
Estimated Expiration
2043-04-13

AI Technical Summary

Technical Problem

The therapeutic effect and safety of existing anti-inflammatory drugs and immunosuppressants in the treatment of inflammatory bowel disease are insufficient, and the health efficacy of intestinal microorganisms to transform barley leaves has not been reported, and a new, safe and effective prevention is urgently needed. Methods for inflammatory bowel disease.

Method used

The barley leaf powder was fermented with mouse intestinal microorganisms under an anaerobic environment to prepare barley leaf biotransformants. The barley leaf biotransformation with special microbial communities was obtained. , used to treat and prevent intestinal diseases and improve intestinal barrier function.

Benefits of technology

Barley leaf biotransformants significantly inhibit weight loss, diarrhea and colon shortening in the mouse colitis model, reduce the pathological damage to the colon tissue of mice, improve mucus barrier function, improve inosine and guanosine content, and significantly improve intestinal health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116406789B_ABST
    Figure CN116406789B_ABST
Patent Text Reader

Abstract

The present application discloses a preparation method and application of a barley leaf biotransformation product. The present application fully mixes barley leaf powder, mouse intestinal contents and a buffer solution according to a certain dosage ratio, and performs in vitro fermentation culture under constant temperature and oscillation conditions in an anaerobic environment to obtain a barley leaf biotransformation product suspension culture solution; centrifuges, collects the supernatant, and obtains the barley leaf biotransformation product. The present application applies the barley leaf biotransformation product to a mouse colitis model. Compared with the barley leaf group that has not undergone biotransformation, the barley leaf biotransformation product shows better effects in increasing the content of inosine and / or guanosine, inhibiting weight loss, diarrhea and colon shortening; in addition, the barley leaf biotransformation product has a better effect in reducing pathological damage to mouse colon tissue and improving mucus barrier destruction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a preparation method and application of a barley leaf biotransformation product, and in particular to a preparation method and application of a barley leaf biotransformation product using barley leaves as raw materials and achieving nutrient biotransformation through mouse intestinal microbial fermentation. Background Art

[0002] Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic intestinal inflammatory disease characterized by weight loss, severe diarrhea and abdominal pain, posing a huge safety threat to human health. Currently, anti-inflammatory drugs and immunosuppressants are the main treatments for IBD, however, drug therapy still has many defects in terms of therapeutic effect and safety. Therefore, there is an urgent need to find a new, safe and effective product for the prevention of IBD.

[0003] There are a large number of microorganisms in the intestines of humans and animals, called intestinal microorganisms. It is estimated that the human intestinal microbiome is composed of about 10 to 100 trillion microbial cells, which is about 10 times the number of human cells. These microorganisms play an important role in metabolizing dietary nutrients, promoting the development of the immune system, and resisting the invasion of pathogenic microorganisms. After millions of years of interactive evolution, the host has established an inseparable symbiotic relationship with these microorganisms.

[0004] The intestinal barrier composed of the host's intestinal epithelial cells spatially isolates intestinal microorganisms from the host, preventing harmful components of intestinal microorganisms from transferring through the intestinal wall into the body and causing excessive inflammatory responses. Goblet cells are a special type of intestinal epithelial cells that can produce and secrete mucin Muc2 into the intestinal cavity to form a mucus layer. As an important component of the intestinal barrier, the intestinal mucus barrier composed of the inner mucus layer and the outer mucus layer effectively protects intestinal epithelial cells from infection and physical damage, and plays an important role in maintaining the long-term balance and stability of intestinal homeostasis. However, the destruction of the intestinal barrier function can cause intestinal microecological disorders, which are closely related to the occurrence of inflammatory bowel disease.

[0005] Barley leaves are fresh tender stems and leaves harvested from the early growth of the crop barley (Hordeum vulgare L.). They are also traditional Chinese medicine and food. They are rich in dietary fiber, chlorophyll, flavonoids, vitamins, antioxidant enzymes, and a variety of metal minerals, which are active ingredients that play an important role in the health of the body. There have been historical records of the nutrition and efficacy of barley leaves in my country since ancient times. In recent years, "wheat straw food" produced with young barley leaves as raw materials has been very popular in many regions. Due to its green and natural characteristics, it will have a broad market in the future. However, there are no reports on the health benefits of intestinal microbial transformation of barley leaves at home and abroad. Summary of the invention

[0006] In view of the above problems existing in the prior art, the first technical problem to be solved by the present invention is to provide a method for preparing barley leaf biotransformation products; the second technical problem to be solved by the present invention is to provide barley leaf biotransformation products prepared by the method; the third technical problem to be solved by the present invention is to provide the use of barley leaf biotransformation products.

[0007] To solve the above problems, the present invention provides the following technical solutions:

[0008] A preparation method using barley leaves as raw materials and achieving nutrient bioconversion through mouse intestinal microbial fermentation, comprising the following steps:

[0009] The barley leaves were crushed to obtain barley leaf powder; the barley leaf powder, mouse intestinal contents and buffer were fully mixed according to a certain dosage ratio, and in vitro fermentation culture was carried out under constant temperature and shaking conditions in an anaerobic environment until the bacterial concentration reached 1×10 8 cfu / mL or more, and obtain a barley leaf biotransformation product suspension culture solution; centrifuge the barley leaf biotransformation product suspension culture solution, collect the supernatant, and obtain the barley leaf biotransformation product.

[0010] Preferably, the barley leaves are young leaves of barley seedlings of the grass family.

[0011] Preferably, fresh tender stems and leaves of barley seedlings grown to 15 to 30 cm are harvested, dried, and then crushed, and the barley leaf powder is obtained after crushing and screening.

[0012] Preferably, fresh tender stems and leaves of wheat seedlings with a length of 15 to 30 cm are harvested, washed with water, cut into pieces, and dried in a freeze dryer at 60° C. for 24 hours. The dried barley leaves are crushed with a blender for 1 minute and sieved through a 300-mesh sieve to obtain barley leaf powder.

[0013] Preferably, the intestinal contents of 8-week-old C57Bl / 6J female mice are collected.

[0014] Preferably, the relative abundance ratio of Firmicutes in the intestinal contents of mice is 28% to 58%, and the relative abundance ratio of Bacteroidetes is 30% to 55%.

[0015] Preferably, the relative abundance ratio of Firmicutes in the intestinal contents of mice is 42.74±14.81%, the relative abundance ratio of Bacteroidetes is 42.58±11.95%, the relative abundance ratio of Proteobacteria is 0.28±0.16%, the relative abundance ratio of Actinobacteriota is 0.53±0.22%, the relative abundance ratio of Verrucomicrobiota is 0.22±0.13%, and the relative abundance ratio of Desulfobacterota is 0.31±0.18%.

[0016] Preferably, the barley leaf powder, mouse intestinal contents and buffer are fully mixed according to a dosage ratio of 1 g: (6-10) g: 20 ml.

[0017] Preferably, the buffer is PBS buffer.

[0018] Preferably, the volume fraction of CO2 in the anaerobic environment is 20%, and the volume fraction of N2 is 80%.

[0019] Preferably, the constant temperature shaking condition is 35-39° C., the rotation speed is 200-240 rpm, and the culture is carried out for 22-26 hours.

[0020] Preferably, the constant temperature shaking condition is 37° C., the rotation speed is 220 rpm, and the culture is carried out for 24 hours.

[0021] The barley leaf biotransformation product prepared by the above method is also within the protection scope of the present invention.

[0022] Application of barley leaf biotransformation products in improving the changes of inosine content.

[0023] Application of barley leaf biotransformants in improving changes in guanosine content.

[0024] Application of barley leaf biotransformation products in the preparation of drugs for treating and / or preventing intestinal diseases and improving intestinal barrier function.

[0025] Preferably, the intestinal barrier function includes a physical barrier composed of intestinal epithelial cells and a chemical barrier composed of mucus-producing goblet cells.

[0026] Preferably, improving the intestinal barrier function is promoting intestinal epithelial cell proliferation and / or increasing intestinal mucus.

[0027] Preferably, the active ingredient of the medicament is barley leaf biotransformation product.

[0028] Preferably, the drug further contains a pharmaceutically acceptable carrier or excipient.

[0029] Beneficial effects achieved by the present invention:

[0030] The present invention provides a method of using fresh barley leaves as raw materials, achieving biotransformation of nutrients by mouse intestinal microorganisms under appropriate time, oxidation and temperature conditions to obtain a barley leaf biotransformation product having a special microbial community composition. The barley leaf biotransformation product is applied to a mouse colitis model. Compared with a blank control group and a barley leaf group that has not undergone biotransformation, the barley leaf biotransformation product shows better effects in inhibiting weight loss, diarrhea, and colon shortening. In addition, the barley leaf biotransformation product has a better effect in reducing pathological damage to mouse colon tissue and improving mucus barrier destruction. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the technical solution of the present application, the drawings required for use in the embodiments are briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.

[0032] Figure 1 This is a principal component analysis diagram of the microbial composition of barley leaves before bioconversion (before fermentation) and after bioconversion (after fermentation) in Example 2;

[0033] Figure 2 α diversity analysis diagram of barley leaves before bioconversion (before fermentation) and after bioconversion (after fermentation) in Example 2;

[0034] Figure 3 This is a comparison chart of the relative abundance of Firmicutes and Proteobacteria in the barley leaves before bioconversion (before fermentation) and after bioconversion (after fermentation) in Example 2;

[0035] Figure 4 This is a comparison chart of the relative abundance of Helicobacteraceae and Prevotellaceae in the barley leaves of Example 2 before bioconversion (before fermentation) and after bioconversion (after fermentation);

[0036] Figure 5 This is a comparison chart of the relative abundance of Dubosiella and Rikenella in the barley leaves of Example 2 before bioconversion (before fermentation) and after bioconversion (after fermentation);

[0037] Figure 6 This is a comparison chart of the changes in inosine content in the barley leaf group before bioconversion (unfermented barley leaf group) and the barley leaf group after bioconversion (barley leaf fermentation product group) of Example 2;

[0038] Figure 7 This is a comparison chart of the changes in guanosine content in the barley leaf group before bioconversion (unfermented barley leaf group) and the barley leaf group after bioconversion (barley leaf fermentation product group) of Example 2;

[0039] Figure 8 This is a graph showing the effects of the barley leaf group before bioconversion (unfermented barley leaf group) and the barley leaf group after bioconversion (fermented barley leaf group) on the body weight of mice in Example 3;

[0040] Fig. 9 This is a graph showing the effects of the barley leaf group before bioconversion (unfermented barley leaf group) and the barley leaf group after bioconversion (barley leaf fermentation product group) on the disease activity index (DAI) of mice in Example 3;

[0041] Fig.10 This is a graph showing the effect of the barley leaf group before bioconversion (unfermented barley leaf group) and the barley leaf group after bioconversion (fermented barley leaf group) on the colon length of mice in Example 3;

[0042] Fig.11 This is a graph showing the effects of the barley leaf group before bioconversion (unfermented barley leaf group) and the barley leaf group after bioconversion (barley leaf fermentation product group) in Example 3 on pathological damage to mouse colon tissue and mucus barrier. DETAILED DESCRIPTION

[0043] The specific implementation methods of the present application are described in detail below. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present application.

[0044] Example 1: Preparation of barley leaf biotransformation products

[0045] Fresh young stems and leaves of wheat seedlings with a length of 15 to 30 cm were harvested, washed with water, cut into pieces, and dried in a freeze dryer at 60°C for 24 hours. The dried barley leaves were crushed with a blender for 1 minute, sieved through a 300-mesh sieve, and stored at -20°C until use.

[0046] 3-5 g of intestinal contents of 8-week-old C57Bl / 6J female mice were collected and placed in 10 ml of PBS buffer, 0.5 g of barley leaves were added, and the mixture was vortexed for 5 minutes. The suspension sample was transferred to an anaerobic gas-generating bag of Mitsubishi MGC AnaeroPack series, which was sealed to form an anaerobic environment (20% CO2, 80% N2). The bag was placed on a constant temperature shaker at 220 rpm and 37°C for shaking culture for in vitro fermentation for 24 hours to obtain a suspension culture of barley leaf biotransformation products. The suspension culture of the barley leaf biotransformation products was centrifuged at 2000 g for 20 minutes, repeated twice, and the supernatant was collected to obtain barley leaf biotransformation products.

[0047] Example 2: Analysis of microbial composition of barley leaf bioconversion products

[0048] The microbial composition of barley leaves before and after bioconversion was compared and analyzed using 16S rRNA sequencing technology to characterize the changes in microbial community characteristics before and after bioconversion. The genomic DNA of barley leaves before and after bioconversion was extracted, and the variable region of the V3-V4 region of the 16S rRNA gene was PCR amplified using specific primers using the DNA sample as a template to establish a sequencing library. The sequencing library was sequenced using the Illumina Miseq sequencing platform, and the data of each sample was distinguished according to the Index sequence. In the QIIME software, the non-repetitive sequences were clustered into operational taxonomic units (OTUs) according to 97% similarity, and the SILVA database was used for taxonomic analysis. The MOTHUR software was used to calculate the rarefaction curve of each sequencing sample, the community richness Chao1 and ACE index, and the community diversity Shannon and Simpson index. The data differences were reflected on the two-dimensional coordinate graph by principal component analysis, and the samples were subjected to linear discriminant analysis by LEfSe software to find out the communities or species with significant differences.

[0049] After sequence removal, quality control, and OTU clustering, a total of 337 OTUs with a similarity level of 97% were obtained.

[0050] Figure 1 This is the principal component analysis diagram of the microbial composition of barley leaves before and after bioconversion; the abscissa PC1 is 25.36% and the ordinate is 15.51%.

[0051] Figure 2 α-diversity analysis diagram of barley leaves before and after bioconversion; Figure 2 It can be seen that the α diversity of microbial composition after barley leaf bioconversion is higher than that before bioconversion.

[0052] Figure 3is a comparison of the relative abundance of microbial colonies at the phylum level in barley leaves before and after bioconversion; Figure 3 It can be seen that the relative abundance of Firmicutes in barley leaves before biotransformation was 42.75%, and the relative abundance of Firmicutes after biotransformation was 37.58%, and the content decreased; the relative abundance of Proteobacteria in barley leaves before biotransformation was 0.28%, and the relative abundance of Proteobacteria after biotransformation was 0.75%, and the content increased.

[0053] Figure 4 is a comparison of the relative abundance of microbial colonies at the bacterial family level in barley leaves before and after bioconversion; Figure 4 It can be seen that the relative abundance of Helicobacteraceae in barley leaves before bioconversion was 5.28%, and the relative abundance of Helicobacteraceae after bioconversion was 14.61%, and the content increased; the relative abundance of Prevotellaceae in barley leaves before bioconversion was 2.06%, and the relative abundance of Prevotellaceae after bioconversion was 1.53%, and the content decreased.

[0054] Figure 5 is a comparison of the relative abundance of microbial colonies at the genus level in barley leaves before and after bioconversion; Figure 5 It can be seen that the relative abundance of Dubosiella in barley leaves before biotransformation was 0.25%, and the relative abundance of Dubosiella after biotransformation was 1.56%, and the content increased; the relative abundance of Rikenella in barley leaves before biotransformation was 1.58%, and the relative abundance of Rikenella after biotransformation was 0.49%, and the content decreased.

[0055] Figure 6 The comparison chart of the changes in inosine content in barley leaves before and after bioconversion is as follows: Figure 6 It can be seen that the inosine content of barley leaves before biotransformation was 258.01 μg / ml, and the inosine content after biotransformation was 709.69 μg / ml, which is an increase.

[0056] Figure 7 The following is a comparison of the changes in guanosine content in barley leaves before and after biotransformation: Figure 6 It can be seen that the guanosine content of barley leaves before biotransformation was 169.65 μg / ml, and the guanosine content after biotransformation was 543.92 μg / ml, which is an increase.

[0057] Among them, barley leaf before biotransformation refers to the period after barley leaf powder, mouse intestinal contents and buffer solution are mixed and before anaerobic fermentation culture.

[0058] Example 3: Evaluation of the function of barley leaf biotransformation products in a colitis model induced by dextran sulfate sodium (DSS) A colitis model was induced in mice using DSS. The model was established as follows:

[0059] Barley leaf biotransformation products and non-biotransformed barley leaves were transferred to antibiotic-treated C57Bl / 6J mice by gavage at a dose of 200 μl, with 5 gavages performed in 2 weeks. Antibiotic-treated mice were treated with an antibiotic mixture (100 mg / L neomycin, 50 mg / L streptomycin, 100 mg / L penicillin, 50 mg / L vancomycin and 100 mg / L metronidazole) added to their drinking water before gavage for 7 consecutive days to eliminate intestinal microorganisms.

[0060] 24 hours after gavage with barley leaf biotransformation products and non-biotransformed barley leaves, DSS was added to the drinking water of the two groups of mice at a ratio of 2.5% mass fraction, and the mice were allowed to drink water freely for 7 consecutive days to induce colitis. During the induction process, the body weight and fecal status of the mice were recorded daily. After the experiment, the mice were dissected, the colon length was measured, photos were taken, the colon contents were collected, and the colon tissue samples were preserved with 4% formalin fixative to detect colon tissue pathological damage and changes in the degree of improvement of mucus barrier destruction.

[0061] Among them, the weight comparison data of the two groups of mice are as follows Figure 8 As shown, from Figure 8 It can be seen that 7 days after DSS induction, the body weight of mice in the barley leaf group without bioconversion was 84.41% of the initial body weight, and the body weight of mice in the barley leaf bioconversion product group was 88.39% of the initial body weight. Compared with the barley leaf group without bioconversion, the weight loss trend of mice in the barley leaf bioconversion product group was significantly reduced, and the difference was significant (p<0.05), indicating that barley leaf bioconversion product can significantly inhibit DSS-induced weight loss in mice.

[0062] Disease activity index (DAI) is an important indicator for evaluating the severity of colitis model by combining the sum of the scores of three indicators: percentage of weight loss, stool looseness and rectal bleeding. The DAI comparison data of the two groups of mice are shown in Fig. 9 As shown, from Fig. 9 It can be seen that compared with the barley leaf group mice that did not undergo biotransformation, the DAI of the mice in the barley leaf biotransformation product group was significantly reduced, that is, the symptoms of colitis in the mice were significantly improved, indicating that barley leaf biotransformation product can significantly improve the DSS-induced disease activity index of mice.

[0063] Colon length is another important reference indicator for evaluating the severity of colon inflammation. Fig.10 The colon length comparison data of two groups of mice, the upper picture is the actual comparison picture, and the lower picture is the data comparison picture. Fig.10 It can be seen that compared with the barley leaf group mice that did not undergo biotransformation, the barley leaf biotransformation product group mice had longer colon length, that is, the barley leaf biotransformation product group was able to significantly improve the shortening of colon length induced by DSS.

[0064] Intestinal barrier function, including the physical barrier composed of intestinal epithelial cells and the chemical barrier composed of mucus-producing goblet cells, Fig.11 The results of colon tissue sections stained with hematoxylin / eosin and alcian blue showed that the pathological damage of colon tissue and the degree of improved mucus barrier destruction were significantly reduced in the mice treated with barley leaf biotransformation products compared with those in the mice treated with barley leaf biotransformation products without biotransformation.

Claims

1. A method for preparing barley leaf biotransformation products, It is characterized in that The following steps are involved: The barley leaves were crushed to obtain barley leaf powder; the barley leaf powder, mouse intestinal contents and PBS buffer were fully mixed in a dosage ratio of 1 g: (6-10) g: 20 ml, and in vitro fermentation culture was carried out in an anaerobic environment under constant temperature and shaking conditions until the total viable bacteria concentration of the microorganisms reached 1×10 8 cfu / mL or more, obtaining a barley leaf biotransformation product suspension culture solution; centrifuging the barley leaf biotransformation product suspension culture solution, collecting the supernatant, and obtaining a barley leaf biotransformation product, wherein the constant temperature oscillation condition is 35-39° C., the rotation speed is 200-240 rpm, and the culture is carried out for 22-26 hours; the relative abundance ratio of Firmicutes in the intestinal contents is 28%-58%, and the relative abundance ratio of Bacteroidetes is 30%-55%; the CO in the anaerobic environment is 2 The volume fraction is 20%, N 2 The volume fraction is 80%.

2. The method for preparing the barley leaf biotransformation product according to claim 1, It is characterized in that The fresh tender stems and leaves of barley seedlings grown to 15 to 30 cm are harvested, dried, crushed, and screened to obtain barley leaf powder.

3. The barley leaf biotransformation product prepared by the method according to any one of claims 1 to 2.

4. Use of the barley leaf biotransformation product according to claim 3 in increasing the content of inosine and / or guanosine.

5. Use of the barley leaf biotransformation product according to claim 3 in the preparation of drugs for treating and / or preventing intestinal diseases and improving intestinal barrier function.